The retrospective design relies on diagnostic coding, which can vary across providers, and factors such as baseline visual acuity and medication adherence were not fully captured
Semaglutide has been used since 2021 under the brand name, Wegovy, to treat patients with a BMI of 30 or more and patients with a BMI of 27 or more with co-existing weight-related medical problems, including high blood pressure, high cholesterol, obstructive sleep apnea, or heart/vascular disease.[4] As I mentioned above, semaglutide is circulated throughout the body and takes roughly one week to be eliminated through the urine and feces.[5] During its circulation, it interacts with several organs that work together to contribute to weight loss
Managing side effects Side effects are the most common reason people discontinue semaglutide or fail to reach therapeutic doses
Gut dysbiosis impacts the immune system and promotes prostate cancer
Most commonly taken orally, SARMs remain popular (boxer Ryan Garcia failed a drug test for them recently) and are similar to steroids in that they target androgen receptors
Drug costs With benefits far beyond weight loss, patient uptake is rising